Core Insights - The Hang Seng Index has surpassed the 27,300 level for the first time since summer 2021, driven by positive corporate developments [1][2] - Notable stock movements include NIO Inc. with a 5% increase in shares due to a 64.1% year-on-year rise in vehicle deliveries, Ascletis Pharma Inc. with a 12.8% jump following a share buyback announcement, and Alibaba's 4% rise after JPMorgan raised its price target by over 40% [1][2] Market Performance - Since September 1, the Hang Seng Index has gained over 7% [2] - The index has shown strong support around the psychological level of 26,000, with bullish momentum leading to a significant upward movement [5][6] Technical Analysis - The index has broken above a corrective bull flag pattern, indicating a resumption of the uptrend [6] - The September high near 27,000 was convincingly breached, suggesting a demand-supply imbalance favoring buyers [7] - The price is currently trading in the upper half of the blue channel, indicating strong buying interest [7] Indicators - The RSI indicator has entered overbought territory, suggesting potential profit-taking and a possible correction in the future [8]

Market Overview - The Hong Kong stock market opened positively in October, with major indices showing strong performance, including the Hang Seng Index rising 1.61% to 27,287.12 points, and the Hang Seng Technology Index increasing by 3.36% to 6,682.86 points, marking near four-year highs [1] - The market is supported by the resumption of US-China negotiations and expectations of overseas interest rate cuts, which have alleviated liquidity pressures in Hong Kong and led to increased southbound capital inflows [1] Blue-Chip Stocks Performance - Semiconductor company SMIC (00981) reached a new high, closing up 12.7% at HKD 89.65, contributing 71.26 points to the Hang Seng Index. Goldman Sachs remains optimistic about SMIC's long-term order expansion due to market share growth among downstream clients and the increasing semiconductor content in electronic devices [2] - Other notable blue-chip performances include Xinyi Solar (00968) up 9.88%, Kuaishou-W (01024) up 8.57%, while China Resources Mixc Lifestyle (01209) and Chow Tai Fook (01929) saw declines of 2.9% and 2.44% respectively [2] Sector Highlights Technology Sector - Major technology stocks performed well, with Kuaishou rising over 8%, Baidu up over 4%, and Alibaba increasing by over 3%. Chip stocks also surged, with SMIC and Huahong Semiconductor reaching new highs [3] Gold Stocks - Gold stocks experienced a significant rally, with China Silver Group (00815) up 30.19%, and Tongguan Gold (00340) up 15.13%. The international gold price reached new records, with spot gold nearing USD 3,900 per ounce, driven by expectations of a Federal Reserve rate cut [5] Pharmaceutical Sector - Pharmaceutical stocks showed strong performance, with Clover Biopharmaceuticals-B (02197) up 21.15% and Genscript Biotech-B (01672) up 14.44%. The sector is buoyed by anticipated catalysts from upcoming industry conferences and ongoing progress in licensing deals for innovative drugs [6] Automotive Sector - The automotive sector saw broad gains, with NIO-SW (09866) up 6.62% and Li Auto (09875) reporting a 36.8% year-on-year decline in deliveries, marking a continuous drop for four months [7] Notable Stock Movements - Xipin (02583) surged 71.13% to HKD 181.4, primarily involved in the design and manufacturing of gold watches [8] - Kuaishou-W (01024) continued its upward trend, driven by its AI model's performance in global benchmarks [9] - Shenzhou International (02313) rose 7.87% following positive earnings from its core client Nike, which reported revenue of USD 11.7 billion, exceeding market expectations [10] - Contemporary Amperex Technology Co. (03750) reached a new high, closing up 5.95% as it maintains a leading global market share in battery production [11] - New Ming China (02699) experienced a drastic decline of 84.2%, attributed to significant stock transfers and market activity [12][13]

Group 1 - Pharmaceutical stocks are experiencing a strong rally, with notable increases in share prices for companies such as Clover Biopharmaceuticals (up 20.26%), Genscript Biotech (up 15.05%), and others [1] - On September 26, former President Trump announced a 100% tariff on any brand or patented pharmaceutical products starting October 1, 2025, unless companies establish manufacturing facilities in the U.S. [1] - Southwest Securities predicts uncertainty regarding the implementation of this executive order, suggesting that Chinese innovative drug companies heavily reliant on the U.S. market may face short-term pressure [1] - China’s innovative drug companies that engage in business development (BD) overseas are expected to be less affected, particularly those involved in license-out agreements, which are essentially intellectual property transactions [1] - China Post Securities believes the actual impact of the tariffs will be minimal, viewing the current price drop as a good opportunity to increase holdings in innovative drugs [1] Group 2 - From the perspective of catalysts in the innovative drug sector, October will see significant industry conferences such as ESMO (October 17-21), followed by ASH and the San Antonio Breast Cancer Symposium in December [2] - There has been ongoing progress in outbound licensing transactions this year, with several significant deals already completed, indicating potential opportunities for high-quality domestic innovative drugs to enter international markets [2] - The fourth quarter is expected to bring domestic policy implementations, including adjustments to the medical insurance catalog [2]

腾讯控股盘中一度涨3%报683港元，续刷四年半来新高，腾讯年内累涨64%； 中国金表品牌西普尼挂牌翌日再飙72%； 歌礼制药拉升涨近13%，拟斥最多3亿元回购股份； 其他科技股中，中芯国际涨超9%领涨恒生科技指数成分股，快手涨超6%，华虹半导体、比亚迪电子涨 超5%，蔚来、百度涨超4%。 | 代码 | 名称 | ● | 最新 | 涨幅% | 年初至今涨幅% | | --- | --- | --- | --- | --- | --- | | HSTECH | 恒生科技指数 | 1 | 6637.65 | 2.66 | 48.56 | | મટા | 恒生指数 | RIC | 27245.68 | 1.45 | 35.82 | | HSCEl | 恒生国企指数 | 1 | 9711.03 | 1.63 | 33.21 | 来源：格隆汇APP 格隆汇10月2日｜港股承接假期前强势，第四季开局强势，尽管A股假期休市，买盘依然炽热。截至半 日收盘，恒指涨1.45%升破27000点，恒生科技指数涨2.66%，国企指数涨1.63%。 板块方面，科技股、锂电池、半导体、黄金股表现强势，内银股、内房股、新消费普跌。 个股方面， ...

Core Viewpoint - The company, Gilead Sciences (1672.HK), announced a share buyback plan, which has led to a nearly 13% increase in its stock price, reaching HKD 11.25. The buyback is intended to enhance shareholder value and reflects the company's confidence in its long-term business prospects [1]. Financial Position - The company stated that its current financial condition is stable, allowing it to allocate up to HKD 300 million for the share buyback [1]. - The buyback authorization permits the company to repurchase up to 96.2846 million shares, which is equivalent to 10% of the total issued shares [1]. Strategic Intent - The board believes that the proposed share buyback will increase the value of the shares and improve returns for shareholders [1]. - The decision to repurchase shares demonstrates the company's confidence in its growth potential and long-term business outlook, which is expected to ultimately benefit the company and its shareholders [1]. - The company will ensure that the buyback does not significantly impact its operating capital [1].

Core Viewpoint - The company, Gilead Sciences (1672.HK), announced a share buyback plan, which has led to a nearly 13% increase in its stock price, reflecting confidence in its long-term business prospects and growth potential [1] Group 1: Share Buyback Announcement - The company plans to utilize up to 300 million HKD from its internal financial resources for the proposed share buyback [1] - The buyback authorization allows the company to repurchase up to 96.2846 million shares, representing 10% of the total issued shares [1] - The board believes that the share buyback will enhance shareholder value and returns [1] Group 2: Financial Health and Confidence - The company stated that its current financial condition is stable [1] - The proposed buyback reflects the company's confidence in its long-term business outlook and growth potential [1] - The company will ensure that the buyback does not significantly adversely affect its operating capital [1]

Core Viewpoint - The Hong Kong stock market for innovative drug concepts has strengthened, with significant gains in various pharmaceutical companies following the postponement of drug tariffs by the Trump administration [1] Group 1: Market Performance - Companies such as Kelun-Biotech and Gilead Sciences saw their stock prices rise over 8% - Hengrui Medicine increased by over 6% - Companies like Tongyuan Kang Pharmaceutical and Xiansheng Pharmaceutical rose over 5% - Hansoh Pharmaceutical and Innovent Biologics gained over 4% - Companies such as Sihuan Pharmaceutical, Fuxing Pharmaceutical, Shiyao Group, and 3SBio increased by over 3% [1] Group 2: Regulatory Environment - President Trump had previously threatened to impose three-digit tariffs on drug imports starting Wednesday, but the White House indicated that these tariffs may not need to be implemented [1] Group 3: Industry Insights - Pacific Securities released a research report suggesting that attention should be paid to several factors: 1) Changes in Federal Reserve interest rate policies 2) Marginal changes in investment and financing 3) Gradual recovery of overseas demand 4) Sino-US relations and geopolitical factors 5) Class B medical insurance directory and commercial insurance [1]

Core Viewpoint - The company, Gilead Sciences-B (01672), has seen its stock price increase by over 10% following the announcement of a share buyback program, reflecting confidence in its long-term business prospects and growth potential [1] Group 1: Share Buyback Announcement - Gilead Sciences announced its intention to repurchase shares based on the general authorization granted by shareholders at the annual general meeting held on May 22 this year [1] - The company is authorized to buy back up to 96.2846 million shares, which represents 10% of the total issued shares (excluding treasury shares) as of the date of the annual general meeting [1] - The board has decided to exercise the buyback authorization and will repurchase shares in the open market as market conditions permit, using up to HKD 300 million from internal financial resources [1] Group 2: Confidence in Business Prospects - The board believes that the proposed share buyback reflects the company's confidence in its long-term business outlook and growth potential [1] - The buyback is expected to benefit the company and align with the overall best interests of the company and its shareholders [1]

于2025年9月29日，董事会已决定行使购回授权，并根据市况不时于公开市场购回股份，以使用最多3亿 港元的资金(拨付自公司内部财务资源)进行建议股份购回。董事会相信，建议股份购回反映公司对自身 的长远业务前景及公司的增长潜力充满信心，且最终将可惠及公司，并符合公司及公司股东整体的最佳 利益。 消息面上，歌礼制药公布，其拟根据公司股东于今年5月22日举行的公司股东周年大会上授予董事会购 回公司股份的一般授权行使其权力，在合适时间于公开市场上购回股份。根据购回授权，公司获准购回 最多9628.46万股股份，相当于股东周年大会日期已发行股份(不包括库存股份)总数的10%。 智通财经APP获悉，歌礼制药-B(01672)涨超10%，截至发稿，涨10.23%，报10.99港元，成交额4277.41 万港元。 ...

公司现时的财务状况稳健。董事会认为股份现时的成交价未能反映其内在价值。董事会相信，建议股份 购回可提升股份的价值，从而提高公司股东的回报。此外，董事会相信，建议股份购回反映公司对自身 的长远业务前景及公司的增长潜力充满信心，且最终将可惠及公司，并符合公司及公司股东整体的最佳 利益。 歌礼制药-B(01672)发布公告，其拟根据公司股东于2025年5月22日举行的公司股东周年大会上授予董事 会购回公司股份的一般授权行使其权力，在合适时间于公开市场上购回股份。根据购回授权，公司获准 购回最多9628.46万股股份，相当于股东周年大会日期已发行股份(不包括库存股份)总数的10%。 于2025年9月29日，董事会已决定行使购回授权，并根据市况不时于公开市场购回股份，以使用最多3亿 港元的资金(拨付自公司内部财务资源)进行建议股份购回。 ...